X
Record #1403

Pre-treatment Levels of Circulating Free IGF-1 Identify NSCLC Patients Who Derive Clinical Benefit From Figitumumab

Original paper date
Jul 26, 2010
Institution
The Department of Clinical Development and Medical Affairs, Pfizer Oncology, New London, CT 06320, USA · Department of Pathology and Laboratory Medicine, Warren Alpert Medical School at Brown University, Providence, RI 02903, USA · Department of Thoracic Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA · HistoRx Inc., New Haven, CT 06511, USA · Department of Medical Oncology, Virgen del Rocio University Hospital, Seville 41013, Spain · Department of Medical Oncology, University of Turin, Orbassano, Turin 10043, Italy · Department of Medical Oncology, West Clinic, Memphis, TN 38120, USA · Hematology/Oncology Division, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA · Department of Medical Oncology, McGill University, Montreal, Quebec H3T 1E2, Canada
Open access
No
Article type
Research Article
Broad categories
(BLS) Biochemistry(BLS) Biology - Cancer(BLS) Biology - Cellular(BLS) Biology - Molecular
Citation lifecycle

How this paper is being cited

Pre-retraction
15
Same day
0
Post-retraction
17
% post-retraction
53.1%
~6.4 citations/yr before retraction · ~1.2 citations/yr after
— citing papers

Who is still citing this work

Loading…
Back to browse